The majority of HLA-DR3 alloreactive T cells is peptide specific, but does not recognize known DR3-bound sequences

Tissue Antigens

Volumn 51, Issue 1, 1998, Pages 88-95

  De Koster, H S ^a   Vermeulen, C J ^a   Koning, F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allorecognition; HLA class II; Human; Peptides; T cells

Indexed keywords

HLA DR3 ANTIGEN; PEPTIDE;

ALLOIMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; CELL CLONE; CELL MUTANT; CONTROLLED STUDY; GRAFT REJECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0031983636     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb02951.x     Document Type: Article

References (38)

1. Hall BM, Dorsch SE. Cells mediating allograft rejection. Immunol Rev 1984: 77: 31-59.
2. Tolkoff-Rubin NE, Rubin RH. Viral infection in the renal transplant recipient (review). Curr Opin Nephrol Hypertens 1992: 1: 143-8.
3. Mentzer SJ, Barbosa JA, Strominger JL, Biro PA, Burakoff SJ. Species-restricted recognition of transfected HLA-A2 and HLA-B7 by human CTL clones. J Immunol 1986: 137: 408-13.
4. Bernhard EJ, Le AX , Yanelli JR et al. The ability of cytotoxic T cells to recognize HLA-A21 or HLA-B7 antigens expressed on murine cells correlates with their epitope specificity. J Immunol 1987: 139: 3614-21.
5. b by alloreactive T lymphocytes. Nature 1989: 341: 749-52.
6. Lombardi G, Sidhu S, Lamb JR, Batchelor JR, Lechler RI. Co-recognition of endogenous antigens with HLA-DR1 by alloreactive human T-cell clones. J Immunol 1989: 142: 753-9.
7. Lombardi G, Sidhu S, Batchelor JR, Lechler RI. Allorecognition of DR1 by T cells from a DR4/DRw13 responder mimics self-restricted recognition of endogenous peptides. Proc Natl Acad Sci U S A 1989: 86: 4190-1.
8. Molina IJ, Huber BT. The expression of a tissue-specific self-peptide is required for allorecognition. J Immunol 1990: 144: 2082-8.
9. Rojo S, Lopez D, Calvo V, Lopez de Castro JA. Conservation and alteration of HLA-B27-specific T-cell epitopes on mouse cells. J Immunol 1991: 146: 634-42.
10. Koster HS de, Anderson DA, Termijtelen A. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. J Exp Med 1989: 169: 1191-6.
11. + alloreactive T-cell clone. J Exp Med 1990: 172: 387-90.
12. Schendel DJ. On the peptide model of allorecognition: cytotoxic T lymphocytes recognize an alloantigen encoded by two HLA-linked genes. Hum Immunol 1990: 27: 229-39.
13. Schroeijers WEM, de Koster HS, Verduyn W, Schreuder GMTh, Termijtelen A. T-cell recognition of class II products that result from the combined presence of two different haplotypes. Hum Immunol 1992: 33: 229-34.
14. Ljunggren HG, Stam NJ, Öhlen C et al. Empty MHC class I molecules come out in the cold. Nature 1990: 346: 476-80.
15. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995: 41: 178-228.
16. Panina-Bordignon P, Corradin G, Roosnek E, Sette A, Lanzavecchia A. Recognition by class II alloreactive T cells of processed determinants from human serum proteins. Science 1991: 252: 1548-50.
17. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993: 178: 27-47.
18. Malcherek G, Falk K, Rötzschke O et al. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int Immunol 1993: 10: 1229-37.
19. Malcherek G, Gnau V, Stevanovic S, Rammensee H-G, Jung G, Melms A. Analysis of allele-specific contact sites of natural HLA-DR17 ligands. J Immunol 1994: 153: 1141-9.
20. Morris P, Shaman J, Attaya M et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994: 368: 551-4.
21. Eastman S, Deftos M, De Roos PC et al. A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody. Eur J Immunol 1996: 26: 385-93.
22. Monji T, McCormack AL, Yates JR 3rd, Pious D. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants. J Immunol 1994: 153: 4468-77.
23. Fung Leung WP, Surh CD, Liljedahl M et al. Antigen presentation and T-cell development in H2-M-deficient mice. Science 1996: 271: 1278-81.
24. Pinet V, Vergelli M, Martin R, Bakke O, Long EO. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995: 375: 603-6.
25. Demotz S, Peleraux A. Processing of DR1-restricted determinants from the fusion protein of measles following two distinct pathways. Mol Immunol 1996: 33: 387-97.
26. Koster HS de, Amons R, Benckhuijsen WE, Feijlbrief M, Schellekens GA, Drijfhout JW. The use of dedicated peptide libraries permits discovery of high affinity binding peptides. J Immunol Methods 1995: 187: 179-88.
27. Rebai N, Malissen B, Dieres M, Acolla RS, Corte G, Mawas C. Distinct HLA-DR epitopes and distinct families of HLA-DR molecules defined by15 monoclonal antibodies either anti-DR or anti allo-Ia crossreacting with human DR molecules. Eur J Immunol 1983: 13: 106-11.
28. Spits H, Borst J, Giphart MJ, Coligan J Terhorst, C de Vries J. HLA-DC antigens can serve as recognition elements for human cytotoxic T lymphocytes. Eur J Immunol 1984: 14: 299-304.
29. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996: 384: 134-11.
30. Schroeijers WEM, de Koster HS, van Rood JJ, Termijtelen A. HLA-DRβIII and HLA-DP induce comparable proliferation in primary mixed lymphocyte cultures. Tissue Antigens 1988: 32: 145-9.
31. Katz JF, Sant AJ. T-cell receptor recognition of MHC class II alloantigen is highly cell type dependent. J Immunol 1994: 152: 1629-40.
32. Geluk A, van Meijgaarden KE, Southwood S et al. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J Immunol 1994: 152: 5742-8.
33. Demotz S, Grey HM, Sette A. The minimal number of class II MHC-antigen complexes needed for T-cell activation. Science 1990: 249: 1028-30.
34. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996: 22: 6144-54.
35. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med 1996: 184: 1747-53.
36. Heath WR, Kane KP, Mescher MF, Sherman LA. Alloreactive T cells discriminate among a diverse set of endogenous peptides. Proc Natl Acad Sci U S A 1991: 88: 5101-5.
37. Rötzschke O, Falk K, Faath S, Rammensee H-G. On the nature of peptides involved in T-cell alloreactivity. J Med 1991: 174: 1059-71.
38. Man S, Salter RD, Engelhard VH. Role of endogenous peptide in human alloreactive cytotoxic T-cell responses. Int Immunol 1991: 4: 367-75.